Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Ambry Genetics, a leader in clinical genomic ...
Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease ALISO VIEJO, Calif., February 02, 2026--(BUSINESS WIRE)--Ambry Genetics, a leader in ...
Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics first implemented RNA testing in 2016 as part of a research and ...
Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary ...
Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the completion of its one-millionth DNA/RNA test, underscoring the ...
New study published in Nature Communications builds on Ambry’s contributions to MAVE research to deepen understanding of PALB2 and its role in hereditary cancer predisposition. PALB2 is one of the ...
Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced its contribution to new research leveraging Multiplexed Assays ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results